BRUKINSA (zanubrutinib)

About BeOne Medicines

BeOne Medicines is building the world's leading oncology company through scientific excellence and global reach, serving patients across 45+ countries with 12,000+ employees. The company has successfully transitioned from development to commercialization with approved therapies generating significant revenue. With substantial U.S. investment including $750M in R&D and a 400,000 square foot manufacturing facility, BeOne is positioned as a major player in global cancer treatment.

Therapeutic Areas